EN DE
Watch Nano Holdings for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Nano Holdings (3NQ) fair value: what the stock is really worth

As of Oct 26, 2026: fair value (intrinsic value) of Nano Holdings stock €0.19, price €0.44, upside -57.0%, quality 45 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare · DE · Home Japan · ISIN JP3651120002

NH Nano Holdings logo Thin data Oct 21, 2026

Nano Holdings

3NQ · F

Weakest SetupStrongly overvalued and low quality.

Our calculation puts a fair price 57% below what the stock costs today.

Low debt
Quality 45/100
Fair value €0.1900 · Strongly overvalued (−57.0%)
Weak Growth (revenue 5y −11.0 %/yr in EUR)
Negative free cash flow
Trails peers (3/8)
Narrow moat 12/100
Thin data
Price via web search⚠ Thinly traded
Watch Nano Holdings for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€2.50 €0.4032 Fair Value €0.1900 Aug 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 21, 2026.

How to read this chart

60‑month range €0.4032 – €2.50 · fair‑value band €0.1300 – €0.2400 · the €0.4421 price screens above the €0.1900 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 21, 2026.

Follow Nano in your weekly email

Every Wednesday you see whether Nano is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Nano Holdings, Inc. researches, develops, produces, and sells pharmaceuticals using micellar nanoparticles technology in Japan.

Show moreShow less

The company's pipeline products include RUNX1 (mRNA) for the treatment knee osteoarthritis and reduces pain; and NC-6100 PRDM14 (siRNA), which is in phase I clinical trials for the treatment of breast cancer. Its product pipeline also comprises TUG1 (ASO) for glioblastoma multiforme.

In addition, it offers cosmetic raw material. The company was formerly known as NANO MRNA Co.,Ltd. and changed its name to Nano Holdings, Inc. in December 2025. Nano Holdings, Inc. was incorporated in 1996 and is headquartered in Minato, Japan.

Stock analysis

Nano Holdings (3NQ) currently trades at €0.4421, while our model-based Fair Value estimate is €0.1900, 57.0% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: €0.1300 (bear) to €0.2400 (bull), the price of €0.4421 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Nano Holdings reported revenue of ¥174M in FY2026 versus ¥264M in FY2022, a compound −9.8%/yr. Reported net income was −¥944M in FY2026.

Key figures

Market cap €43.9M Micro · P/S ratio 0.22 · EPS (TTM) €−0.0700 · Return on equity −34.3% · Return on assets (EBIT) −20.5% · Operating margin −789% · Revenue (TTM) ¥202M · Revenue growth (YoY) +400%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 55% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 2% fair-value upside, at −57%, 3NQ screens richer than that median.

Fair Value models

Bear €0.1300 Fair Value €0.1900 Bull €0.2400
Price €0.4421 · Upside -57.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) €0.1300 €0.1900 €0.2400 55
All 1 models by family
Asset-Based
NCAV (Graham) €0.1300 €0.1900 €0.2400 55

Open the full fair value analysis →

Quality Score breakdown

Overall quality 45/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 90
Are margins and returns getting better?
Cashflow 31
Do the profits arrive as real cash?
Financial strength 67
Debt, balance sheet and risk of trouble
Investment 99
Does it invest with discipline instead of growing at any price?
Low Volatility 58
How calm the share price moves, does not count
Momentum 12
Price trend of the last 3 to 12 months, does not count
Near the 52-week high 3
Distance to the 52-week high, does not count
New shares 13
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 6/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+60.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−11.0%
Start year 2021 (pandemic). Over 10 years: −3.3% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−415.9% (2021) → −553.6% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

3NQ screens overvalued: fair value 57% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Nano Holdings with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 601 stocks

Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 45 · Above median
Fair Value upside −57.0% · Below median
Profitability
Return on assets −16.0% · Below median
Growth and dividend
Revenue growth (quarter YoY) 400.0% · Top 25%
Balance sheet
Debt / equity 0.37× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.84× · Cheaper than median
P/S (12 months) 32.42× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)82 · sector 97
DIVIDEND (yield)0 · sector 24

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $805.02 $1,275 +58% vs 3NQ
Vertex Pharmaceuticals Incorporated VRTX $535.17 $588.69 +10% vs 3NQ
Samsung Biologics Co 207940 1,466,000 KRW 1,612,600 KRW +10% vs 3NQ
WuXi Biologics (Cayman) Inc 2269 HK$45.80 HK$50.38 +10% vs 3NQ
argenx SE ARGX $890.05 $908.40 +2% vs 3NQ
Alnylam Pharmaceuticals, Inc ALNY $225.10 $217.88 −3% vs 3NQ
CSL Limited CSL A$196.70 A$178.56 −9% vs 3NQ
BeOne Medicines AG 6160 HK$231.40 HK$153.62 −34% vs 3NQ
Celltrion, Inc 068270 197,600 KRW 74,944 KRW −62% vs 3NQ
Royalty Pharma plc RPRX $62.15 $19.01 −69% vs 3NQ

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Nano Holdings · Fair Value
€0.1900 −57%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Nano Holdings Fair Value". https://www.fairvalue-calculator.com/stock/3NQ

Frequently asked questions

Is Nano Holdings (3NQ) overvalued or undervalued?
As of Oct 21, 2026, our model estimates a fair value of €0.1900 versus a price of €0.4421, about −57% upside (overvalued).
What is the fair value of 3NQ?
Our model-based fair value for Nano Holdings is €0.1900 (as of Oct 21, 2026), built from audited fundamentals. The current price: €0.4421.
What is the quality score of 3NQ?
Nano Holdings has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Nano Holdings (3NQ)?
Our model-based price target is the fair value of €0.1900 (as of Oct 21, 2026) from 1 valuation models. Cautious scenario €0.1300, optimistic scenario €0.2400. It is a calculation from audited fundamentals, not an analyst target.
What is the Nano Holdings stock forecast for 2026?
Our models put fair value at €0.1900, about −57% upside versus a price of €0.4421 (overvalued). Cautious scenario €0.1300, optimistic scenario €0.2400. The calculation is refreshed regularly with new filings.
What is the revenue of Nano Holdings (3NQ)?
Nano Holdings reported trailing-twelve-month revenue of about ¥202M (latest available figure, as of Oct 21, 2026).
What is the intrinsic value of Nano Holdings (3NQ)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Nano Holdings it is €0.1900 per share (as of Oct 21, 2026), against a price of €0.4421. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Nano Holdings stock overvalued or undervalued in 2026?
As of Oct 21, 2026, 3NQ trades above its calculated fair value: price €0.4421, fair value €0.1900, a gap of about −57% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 3NQ?
No. The price is what the market pays today (€0.4421); the fair value is what the company's own numbers justify (€0.1900). For Nano Holdings the two are €0.2521 per share apart. That gap is exactly why we show both numbers side by side.
How much is Nano Holdings worth?
The market values Nano Holdings at about €43.9M (market capitalisation, as of Oct 21, 2026). Per share that is €0.4421; our models calculate a fair value of €0.1900 per share.
What do the bullish and bearish scenarios say about 3NQ?
Our models span a range for Nano Holdings: cautious scenario €0.1300, base €0.1900, optimistic €0.2400 per share (as of Oct 21, 2026, price €0.4421). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Nano Holdings (3NQ)?
Balance-sheet figures for Nano Holdings (as of Oct 21, 2026): return on equity −34.3%, debt of 0.37 per unit of equity. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is 3NQ from its 52-week high?
Nano Holdings trades at €0.4421, about 55% below its 52-week high of €0.9850 and 12% above the low of €0.3940 (as of Oct 23, 2026). Distance from the high says nothing about value: that is what the fair value of €0.1900 is for.
Which stocks are comparable to Nano Holdings?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Nano Holdings stock attractive at the current price?
The data as of Oct 21, 2026: price €0.4421, calculated fair value €0.1900 (−57%), Quality Score 45/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 3NQ calculated?
We run Nano Holdings through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €0.1900, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 12.5 % above its aggregate fair value. Nano Holdings itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Nano Holdings (3NQ)?
The closing price on Oct 26, 2026 was €0.4421. Our model-based fair value is €0.1900, about −57% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Nano Holdings right now?
The price sits above even our optimistic bull case (€0.2400). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (45/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (€0.1300 to €0.2400) leaves room in how you read the outcome.

Key figures of Nano Holdings

How large is the market capitalisation of Nano Holdings (3NQ)?
The market capitalisation of Nano Holdings is €43.9M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Nano Holdings (3NQ)?
The price-to-sales ratio of Nano Holdings is 0.22 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Nano Holdings (3NQ)?
Earnings per share at Nano Holdings are €−0.0700. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Nano Holdings (3NQ)?
The return on equity (ROE) of Nano Holdings is −34.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Nano Holdings (3NQ)?
On an EBIT basis the return on assets of Nano Holdings is −20.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Nano Holdings (3NQ)?
The operating margin of Nano Holdings is −789% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Nano Holdings (3NQ)?
Revenue at Nano Holdings is growing +400% versus a year earlier (3y avg −4.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Nano Holdings (3NQ) generate?
The free cash flow of Nano Holdings is −¥817M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Nano Holdings in the live analysis

One click puts Nano Holdings on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.